Share on StockTwits

Stock Analysts’ ratings reiterations for Tuesday, July 8th:

Anglo American plc (NASDAQ:AAUKY) had its underweight rating reaffirmed by analysts at JPMorgan Chase & Co..

Automatic Data Processing (NASDAQ:ADP) had its neutral rating reaffirmed by analysts at Goldman Sachs.

Aristocrat Leisure Limited (ASX:ALL) had its buy rating reaffirmed by analysts at Deutsche Bank. The firm currently has a $7.20 price target on the stock. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.

ARM Holdings plc (NASDAQ:ARMH) had its overweight rating reaffirmed by analysts at Barclays.

BAE Systems PLC (NASDAQ:BAESY) had its outperform rating reissued by analysts at RBC Capital.

BG Group plc (NASDAQ:BRGYY) had its equal weight rating reissued by analysts at Barclays.

Baytex Energy Corp (NYSE:BTE) had its neutral rating reiterated by analysts at Credit Suisse.

Evotec AG (NASDAQ:EVTC) had its neutral rating reiterated by analysts at Goldman Sachs.

Global Payments (NYSE:GPN) had its neutral rating reaffirmed by analysts at Goldman Sachs.

Blackhawk Network Holdings (NASDAQ:HAWK) had its neutral rating reissued by analysts at Goldman Sachs.

Heartland Payment Systems (NYSE:HPY) had its neutral rating reiterated by analysts at Goldman Sachs.

3i Group plc (LON:III) had its reduce rating reaffirmed by analysts at Oriel Securities Ltd.

Lam Research (NASDAQ:LRCX) had its outperform rating reissued by analysts at Cowen and Company.

VeriFone Systems (NYSE:PAY) had its neutral rating reaffirmed by analysts at Goldman Sachs.

Roche Holding (NASDAQ:RHHBY) had its neutral rating reiterated by analysts at Zacks. They currently have a $39.00 target price on the stock. Zacks’ analyst wrote, “Roche specializes in oncology drugs. Sales for the first quarter of 2014 missed the Zacks Consensus Estimate. The company has a solid position in the breast cancer market with drugs like Herceptin, Perjeta and Kadcyla, and continues to further strengthen its already dominant position. We are also impressed by its efforts to grow its portfolio beyond oncology to immunology and ophthalmology. However, Roche expects to face generic competition for key drugs such as Valcyte and Xeloda in 2014, which will impact sales. Nevertheless, the oncology portfolio looks as solid as ever and we expect further traction in 2014. We have maintained a Neutral recommendation on the stock.”

Rentokil Initial plc (NASDAQ:RTOKY) had its outperform rating reaffirmed by analysts at RBC Capital.

Smith & Nephew plc (NYSE:SNN) had its hold rating reissued by analysts at Numis Securities Ltd.

Total System Services (NYSE:TSS) had its neutral rating reiterated by analysts at Goldman Sachs.

Wood Group John Plc (NASDAQ:WDGJF) had its overweight rating reaffirmed by analysts at Barclays.

WEX (NYSE:WEX) had its neutral rating reaffirmed by analysts at Goldman Sachs.

Williams Partners L.P. (NYSE:WPZ) had its outperform rating reissued by analysts at Credit Suisse.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.